You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Dara-R

Showing 1 - 25 of 2,816
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial (Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT

Not yet recruiting
  • Multiple Myeloma
  • Dara-VRd intensification, Dara-R maintenance
  • +4 more
  • (no location specified)
Dec 13, 2022

AL Amyloidosis Trial (procedure, drug, other)

Not yet recruiting
  • AL Amyloidosis
  • Autologous Hematopoietic Stem Cell Transplantation
  • +15 more
  • (no location specified)
Aug 28, 2023

Plasma Cell Myeloma Trial (Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone)

Not yet recruiting
  • Plasma Cell Myeloma
  • (no location specified)
Dec 22, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 30, 2021

High-Risk de Novo Multiple Myeloma Trial in Spain (Daratumumab, Bortezomib, Lenalidomide)

Not yet recruiting
  • High-Risk de Novo Multiple Myeloma
  • Badalona, Spain
  • +9 more
Apr 27, 2023

Multiple Myeloma Trial in Worldwide (Dara SC, Dara IV)

Active, not recruiting
Has Results
  • Multiple Myeloma
  • Dara SC
  • Dara IV
  • Boston, Massachusetts
  • +145 more
Jan 17, 2023

Maintenance With Bortezomib Plus Daratumumab After Induction

Recruiting
  • Multiple Myeloma
  • Non-eligible for Autologous Stem Cell Transplantation (ASCT)
  • Arganda Del Rey, Spain
  • +31 more
Sep 15, 2022

Multiple Myeloma Trial in Worldwide (Daratumumab, Pomalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +198 more
Jan 17, 2023

Multiple Myeloma Trial in United States (Daratumumab, Lenalidomide, Bortezomib)

Recruiting
  • Multiple Myeloma
  • Ann Arbor, Michigan
  • +3 more
Jan 19, 2023

Clinical Pathways for Newly Diagnosed Multiple Myeloma

Not yet recruiting
  • Multiple Myeloma
  • Multiple Myeloma Without Mention of Remission
  • Multiple Myeloma Pathway
  • +2 more
  • (no location specified)
Nov 27, 2023

Multiple Myeloma Trial in Torino (Velcade, Melphalan, Prednisone)

Recruiting
  • Multiple Myeloma
  • Torino, TO, Italy
    Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
May 25, 2022

Multiple Myeloma Trial in Worldwide (CC-220, Dexamethasone, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Scottsdale, Arizona
  • +126 more
Jan 10, 2023

Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Edmonton, Alberta, Canada
  • +12 more
Jan 27, 2023

Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)

Not yet recruiting
  • Multiple Myeloma
  • Miami, Florida
    University of Miami
Oct 20, 2023

Multiple Myeloma, Renal Failure Trial in Augusta (Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide,

Not yet recruiting
  • Multiple Myeloma
  • Renal Failure
  • Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
  • Augusta, Georgia
    Georgia Cancer Center-Augusta University
Nov 16, 2023

Multiple Myeloma Trial in Hackensack (Daratumumab, Pomalidomide, All-trans retinoic acid)

Recruiting
  • Multiple Myeloma
  • Hackensack, New Jersey
    John Theurer Cancer Center
Jun 10, 2022

Multiple Myeloma Trial in United States (bb2121, Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Multiple Myeloma
  • bb2121
  • +3 more
  • Scottsdale, Arizona
  • +19 more
Jul 7, 2022

Multiple Myeloma, Monoclonal Gammopathy of Renal Significance Trial in United States (Cyclophosphamide, Bortezomib,

Recruiting
  • Multiple Myeloma
  • Monoclonal Gammopathy of Renal Significance
  • Basking Ridge, New Jersey
  • +6 more
Oct 16, 2023

Severe Maternal Morbidity, Maternal Death Trial in Pittsburgh (Medicaid healthcare quality interventions (equity payment and

Not yet recruiting
  • Severe Maternal Morbidity
  • Maternal Death
  • Medicaid healthcare quality interventions (equity payment and obstetric bundled payment)
  • +2 more
  • Pittsburgh, Pennsylvania
    University of Pittsburgh School of Public Health
Dec 22, 2022

Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)

Withdrawn
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Jan 26, 2023

Multiple Myeloma Trial in Canada, United States (Pomalidomide, Carfilzomib, dexamethasone)

Recruiting
  • Multiple Myeloma
  • Chicago, Illinois
  • +4 more
Jan 7, 2022

Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma Trial in Italy (Daratumumab)

Active, not recruiting
  • Refractory T-Cell Lymphoma
  • Relapsed T-Cell Lymphoma
  • Bari, Italy
  • +6 more
Aug 1, 2022

Plasma Cell Leukemia Trial (Daratumumab)

Not yet recruiting
  • Plasma Cell Leukemia
  • (no location specified)
Sep 22, 2021

Multiple Myeloma Trial in Worldwide (Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib 20 mg/m^2
  • +4 more
  • Gilbert, Arizona
  • +107 more
Dec 20, 2022

Multiple Myeloma Trial (Pembrolizumab)

Withdrawn
  • Multiple Myeloma
  • (no location specified)
Apr 20, 2022